CH, DE, BE and NL: Which Life Sciences Market Is Right for Your Career?

If you have already decided that relocation is the right next step, the question becomes which market will give your career the greatest opportunity to grow. Switzerland, Germany, Belgium and the Netherlands are all leading life sciences markets, but they are not interchangeable. The better question is not “Which country pays the most?” but “Which market best fits the career I am trying to build?”

Switzerland has Europe’s highest average salary, at roughly €6,500 gross per month in 2026. In life sciences, senior regulatory, CMC, medical affairs and clinical‑development roles can command a substantial premium, particularly in the Basel ecosystem.

That premium must be viewed alongside living costs. A two‑bedroom home in Zurich can cost roughly CHF 3,000–4,800 per month; Basel is generally more affordable, although furnished and expat‑targeted homes carry a premium. Cantonal taxes also materially alter take‑home pay: use the Swiss federal tax calculator to compare locations rather than relying on national averages.

Switzerland’s life sciences market is anchored by Roche, Novartis and the surrounding supplier, CDMO and spin‑out ecosystem. It is a powerful choice for professionals targeting that corridor, though it can offer less employer variety than Germany or the Netherlands. Basel’s cross‑border location also makes living in Germany or France a potential housing‑cost strategy, with tax, healthcare and commuting implications.

Best fit: Senior scientific, regulatory and clinical professionals targeting large pharma or the established CDMO ecosystem, who want maximum nominal compensation and are prepared to manage living costs actively.

The Netherlands is highly accessible for internationally mobile life sciences professionals. English is widely used in professional settings, and the 30% facility can allow eligible employees to receive up to 30% of qualifying remuneration tax‑free. The rate remains 30% in 2026 and is scheduled to fall to 27% from 1 January 2027.

The 2026 Dutch income‑tax brackets reach 49.5% above €78,426; the official Belastingdienst table should be used for current thresholds. Partial non‑resident taxpayer status was abolished for new users from 2025, with transitional treatment for certain pre‑2024 holders through the 2026 tax year.

Leiden Bio Science Park is the centre of the Dutch cluster. It reports 26,000 professionals and 27,000 students; the wider campus brings together major pharma, clinical‑stage biotech, research, education and healthcare. Amsterdam adds a growing digital‑health, AI drug‑discovery and commercial‑biotech proposition. Housing needs to be modelled carefully: the Netherlands remains less expensive than Zurich for many households, but the gap has narrowed.

Best fit: Mid‑career RA, clinical operations, biotech CMC and analytical‑development professionals who value international teams, employer diversity and the 30% facility. It is also strong for data and AI professionals moving into life sciences.

Germany offers the deepest employer landscape of the four markets. A European workforce outlook using Lightcast data identified 493,023 life sciences job postings in Germany, the largest volume among the European markets covered. Its ecosystem spans Bayer, Merck KGaA and Boehringer Ingelheim, as well as CDMOs, manufacturing, advanced therapies and academic‑to‑industry pathways.

In 2026, Germany’s 42% marginal rate begins at approximately €69,879 of taxable income, and employee social contributions also shape take‑home pay. Germany is generally more affordable than Switzerland and, outside Munich, often more affordable than Amsterdam or Leiden.

The language issue is practical rather than cosmetic. English can be sufficient in international pharma and certain senior roles, but German materially expands access to GMP manufacturing, quality assurance, local regulatory work and German‑owned organisations. Functional professional proficiency is a long‑term career investment, not an optional extra for professionals who want access to the full market.

Best fit: Senior GMP manufacturing, process‑development, MSAT and RA professionals with German capability, or a genuine plan to build it, who want the widest employer base and long‑term career optionality.

Belgium is smaller than Germany and Switzerland, but its Ghent–Brussels corridor has meaningful depth in advanced therapies, biopharma manufacturing and early‑stage development. The VIB research institute in Flanders is a key anchor: it supports the regional ecosystem and reports a startup portfolio that has raised close to €1.3 billion. Ghent is also investing in new GMP capacity for cell and gene therapy, including a 1,000 m² GMP unit planned to be operational by the end of 2026.

The trade‑off is tax complexity. Belgian personal income‑tax rates range from 25% to 50%, as set out by FPS Finance, with social contributions and local surcharges also relevant. Packages often include benefits such as company cars, meal vouchers and hospitalisation insurance, so professionals should compare total reward and net position rather than salary alone.

English is commonly used in the international life sciences sector, though Flemish/Dutch and French matter for broader integration and some roles. Belgium can offer unusually strong programme ownership prospects for people who want to work close to emerging cell and gene therapy programmes rather than exclusively within mature global‑pharma structures.

Best fit: Cell and gene therapy professionals, advanced‑therapy CMC specialists and early‑clinical regulatory leaders who value programme ownership, specialised modality depth and a more cost‑effective base than Basel or Amsterdam.

Use salary data as a starting point, not a decision. Compare the net package, housing, employer diversity, language requirements, professional network and the type of work you want to be doing in three to five years. Switzerland is strongest for nominal compensation and established pharma; the Netherlands for international accessibility and a diverse cluster; Germany for scale and career depth; and Belgium for advanced‑therapy specialisation and ownership opportunities.

None of these answers is universally correct. The right market is the one that offers the right combination of compensation, employer choice, trajectory and personal sustainability for your profile at this point in your career.

For market advice tailored to your profile, get in touch with the Panda team.